Table 1 Clinicopathologic characteristics of the two independent cohorts of patients with non-WNT/non-SHH MB involved in this study.
Characteristics | Discovery cohort (n = 69) | Validation cohort (n = 32) | P value |
|---|---|---|---|
Age at diagnosis | 0.626 | ||
0–3 | 5 (7.2%) | 4 (12.5%) | |
4–18 | 64 (92.8%) | 28 (87.5%) | |
Sex | 0.382 | ||
Male | 55 (79.7%) | 23 (71.9%) | |
Female | 14 (20.3%) | 9 (28.1%) | |
Tumor location | 1.000 | ||
Midline | 68 (98.6%) | 32 (100%) | |
Hemisphere | 1 (1.4%) | 0 (0%) | |
Tumor size (cm) | 0.876 | ||
≤ 4 | 27 (39.1%) | 12 (37.5%) | |
> 4 | 42 (60.9%) | 20 (62.5%) | |
Metastasis | 0.626 | ||
M0-1 | 64 (92.8%) | 28 (87.5%) | |
M2-3 | 5 (7.2%) | 4 (12.5%) | |
Surgical resection | 0.144 | ||
GTR | 49 (71%) | 18 (56.3%) | |
STR | 20 (29%) | 14 (43.7%) | |
Histology | 1.000 | ||
CMB | 59 (85.5%) | 28 (87.5%) | |
LC/AMB | 10 (14.5%) | 4 (12.5%) | |
Molecular subgroup | 0.601 | ||
G3 | 23 (33.3%) | 9 (28.1%) | |
G4 | 46 (66.7%) | 23 (71.9%) | |
CSI | 0.184 | ||
Yes | 69 (100%) | 30 (93.7%) | |
No | 0 (0%) | 2 (6.3%) | |
Chemotherapy | 0.626 | ||
Yes | 64 (92.8%) | 28 (87.5%) | |
No | 5 (7.2%) | 4 (12.5%) | |
Survival | 0.624 | ||
Living | 44 (63.8%) | 22 (66.7%) | |
Dead | 25 (36.2%) | 10 (33.3%) |
